Navigation Links
Epeius Biotechnologies' Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for the Treatment of Osteosarcoma
Date:7/8/2008

SAN MARINO, Calif., July 8 /PRNewswire/ -- Epeius Biotechnologies Corporation today announced that Rexin-G has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of osteosarcoma. Based on several criteria, including the rarity, seriousness, and current lack of effective therapies for metastatic osteosarcoma, as well as the scientific and medicinal merit of Rexin-G, the granting of Orphan Drug Status by the FDA validates the unique clinical development strategy of Epeius Biotechnologies: that is, to demonstrate the profound single-agent efficacy of Rexin-G where traditional treatments have historically failed.

The FDA Orphan Drug Act was designed to encourage the development of new products that demonstrate significant promise for the treatment of very serious or life-threatening conditions that are relatively rare, affecting fewer than 200,000 persons in the United States. Orphan Drug Designation provides important economic incentives and powerful market protections that encourage the development of innovative products in the cancer field. U.S. Orphan Drug Designation provides seven years of market exclusivity for Rexin-G, a reduction in fees and taxes, and additional regulatory support for R&D initiatives.

About Rexin-G

Rexin-G, the lead product of Epeius Biotechnologies, is the first in a series of tumor-targeted anti-cancer agents designed to seek out and accumulate in metastatic cancers that have spread throughout the body, delivering a lethal payload of genetic medicine to tumor cells and their associated blood supplies without harming normal cells, tissues, or organ systems. Specifically designed to function within the context of the human circulatory system, the demonstration of single agent-efficacy by Rexin-G in Stage IV or metastatic osteosarcoma (ASCO, 2008) is an indication of the remarkable clinical potential of the precision targeting technologies embodied in its design. The
'/>"/>

SOURCE Epeius Biotechnologies
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Epeius Biotechnologies Leads With Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R&D Summit Conference in Boston MA
2. Epeius Biotechnologies Awarded U.S. Patent for Targeted Injectable Gene Delivery In Vivo
3. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
4. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
5. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
6. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Completion of $2,277,000 Equity Financing
7. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Appointment of Mark C. Mirken as its President and Chief Operating Officer
8. Amyris Biotechnologies Announces $70 Million Series B Round
9. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
10. Maven Biotechnologies, LLC to Present at BIOCOM Investor Conference
11. Millennium Biotechnologies, Inc. Launches SURGEX(TM) the First Scientifically Validated Sports Nutritional Product Created from the Medical Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Canada (PRWEB) July 10, 2014 ... present in very low abundance and are often ... challenging and time-consuming. , Join presenters Dr. Rowel ... and Dr. John Anders, Head of Quality at ... spectrometer-based approach that can speed detection and quantitation ...
(Date:7/10/2014)... Francisco, CA (PRWEB) July 10, 2014 ... family closer together. The Archer Family purchased a ... contained within DNA, but ended up with a lifetime ... discoveries contained within the family members’ DNA genuinely brought ... had decided to search deeper into genetic history and ...
(Date:7/10/2014)... Senior supply chain management executives from ... the challenges of “Reducing Cost, Lead Time, & Defects ... sourcing. Describing the partnership of the Bio Supply Management ... Institute ( SCMI) of the University of San ... the Kroc Institute of Peace and Justice in San ...
(Date:7/10/2014)... July 10, 2014 /PRNewswire-iReach/ -- Tute Genomics, ... today announced an agreement with Lineagen, Inc., ... Lineagen,s NextStep Dx PLUS.  Lineagen, focused ... neurological disorders, currently offers FirstStep Dx ... service used by healthcare providers as a ...
Breaking Biology Technology:Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4
... one company is earning their bread and cheese with ... , a global satellite communications provider, has deployed a ... satellite-based broadband access provider. , ,IsoTropic operates an integrated ... 21 acres in rural Wisconsin, and it maintains a ...
... Technologies Inc. , a provider of medical imaging devices and ... has received a notice from the staff of the ... to delisting after missing another opportunity to file financial reports. ... the quarter ended June 30 would serve as an additional ...
... Wis. - A new biofuels company spun out of ... also be presented with the second of two state grants. ... of biofuels, will receive a $115,000 grant as part of the ... . Doyle was on hand to announce the grant, which is ...
Cached Biology Technology:Rural company works to improve broadband 2Madison business receives $115,000 of new state biofuels funding 2
(Date:7/10/2014)... June 27, 2014  Pomerantz LLP has filed ... ("Provectus" or the "Company")(NYSE-MKT: PVCT) and certain of ... States District Court, Middle District of ... of a class consisting of all persons or ... between December 17, 2013 and May 22, 2014, ...
(Date:7/10/2014)... SPRINGS, Florida , July 1, 2014 ... wallets pave way for convenience and improved security: NXT-ID, Inc. ... Inc. (NASDAQ: GOOG ), Apple Inc. (NASDAQ: ... and MasterCard Corporation (NYSE: MA) NXT-ID, Inc., (OTCQB: NXTD) ... is pleased to announce that the second series of 30 ...
(Date:7/10/2014)... COMMACK, N.Y. , July 2, 2014 ... Inc. (ABD) to announce the appointment of the world-renowned ... its Board of Directors. Dr. Ginsburg, with ... two facilities: NY Presbyterian Hospital and Good Samaritan Regional ... Breathing Pacemaker since the late 1980,s and is considered ...
Breaking Biology News(10 mins):SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 4Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 5Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2
... time in wild marine fish populations, new research has shown., ... Institute of Marine Science published today in the academic journal ... in the coral trout, a species found on the Great ... the ozone layer., This is the first time skin cancer ...
... While the flower may attract the bee and the admiring ... of life below ground where the action is. The microbial ... niches immediately surrounding and inside a plant,s rootfacilitates the shuttling ... within the soil matrix. This commerce, by enabling the ...
... in the 2012 Olympics might assume their championship performance ... a new study disproves the classic scientific view that ... The study by biomechanics researchers Matthew W. Bundle at ... Southern Methodist University, Dallas, demonstrates that metabolic economy is ...
Cached Biology News:Skin cancer identified for the first time in wild fish populations 2Getting to the root -- unearthing the plant-microbe quid pro quo 2Getting to the root -- unearthing the plant-microbe quid pro quo 3Getting to the root -- unearthing the plant-microbe quid pro quo 4Getting to the root -- unearthing the plant-microbe quid pro quo 5New study: Running mechanics, not metabolism, are the key to performance for elite sprinters 2New study: Running mechanics, not metabolism, are the key to performance for elite sprinters 3
Human RUNX2/CBFA1 MAb (Clone 232902)...
Whole rabbit blood (any breed, either sex) is collected at the time of slaughter and processed immediately at 4C, bottled, frozen and stored at -70C....
Animal Origin Free...
Goat polyclonal to PINX1 ( Abpromise for all tested applications). entrezGeneID: 54984 SwissProtID: Q548A5...
Biology Products: